ALKS
ALKS clinical trials: Alkermes plc.
Every trial on ClinicalTrials.gov where Alkermes plc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 118
- Trials linked
- 83
- As lead sponsor
- 35
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALKS on the catalyst calendar · ALKS registry changes
- Primary completion Jul 2027Sponsor estimatePhase 2NCT07755410A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity...Alkermes, Inc. · Attention Deficit Disorder With Hyperactivity (ADHD)RecruitingALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 2NCT07901179A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major...Alkermes, Inc. · Major Depressive Disorder (MDD)RecruitingALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 3NCT07540897A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)Alkermes, Inc. · Narcolepsy Type 1RecruitingALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 3NCT07502443A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2Alkermes, Inc. · Narcolepsy Type 2RecruitingALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 3NCT07455383A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1Alkermes, Inc. · Narcolepsy Type 1RecruitingALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2030Sponsor estimatePhase 2/Phase 3NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaAlkermes, Inc. · Narcolepsy Type 1RecruitingALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 2NCT06843590A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaAlkermes, Inc. · Idiopathic HypersomniaActive, not recruitingALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 3NCT05303064Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderAlkermes, Inc. · SchizophreniaRecruitingALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 3NCT04987229Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsAlkermes, Inc. · Bipolar I DisorderEnrolling by invitationALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT07744113An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)Alkermes, Inc. · Bipolar 1 DisorderAvailableALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 19, 2025ActualPhase 2NCT06358950A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)Alkermes, Inc. · Narcolepsy Type 1CompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2025ActualPhase 2NCT06555783A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2Alkermes, Inc. · Narcolepsy Type 2CompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 6, 2023ActualPhase 3NCT03201757Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831Alkermes, Inc. · SchizophreniaCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2023ActualPhase 1NCT04987658Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I DisorderAlkermes, Inc. · Bipolar I DisorderCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2022ActualPhase 1NCT05547100Study of the Breast Milk Pharmacokinetics of Olanzapine and SamidorphanAlkermes, Inc. · Focus of Study is on Healthy Lactating WomenCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 4, 2023ActualNo phase registeredNCT03919994Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)Alkermes, Inc. · SchizophreniaCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2021ActualPhase 3NCT03187769Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia...Alkermes, Inc. · SchizophreniaCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 23, 2022ActualPhase 1NCT05019105Phase 1 ALKS 1140 in Healthy AdultsAlkermes, Inc. · Central Nervous System DiseasesTerminatedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 11, 2017ActualPhase 2NCT02161718A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderAlkermes, Inc. · SchizophreniaCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 2NCT01903837A Study of ALKS 3831 in Adults With SchizophreniaAlkermes, Inc. · SchizophreniaCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 17, 2019ActualPhase 3NCT02873208A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaAlkermes, Inc. · SchizophreniaCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2020ActualPhase 3NCT03610048A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)Alkermes, Inc. · Refractory Major Depressive DisorderTerminatedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2020ActualPhase 3NCT03188185A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)Alkermes, Inc. · Major Depressive DisorderCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2019ActualPhase 3NCT03345979A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaAlkermes, Inc. · SchizophreniaCompletedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 22, 2020ActualPhase 1NCT03963973A 28 Day Parallel Group Study to Assess the Effects of RDN-929Alkermes, Inc. · HealthyTerminatedALKSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 93 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner